Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes
- 27 February 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (11) , 3662-3671
Abstract
Objective: To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy. Methods: We conducted a nationwide retrospective case-control study of GPA with induction failure between 2006 and 2021. Each patient with induction failure was randomly paired to three controls matched for age, sex and induction treatment. Results: We included 51 patients with GPA and induction failure (29 men and 22 women). At induction therapy, median age was 49 years. Twenty-seven patients received intravenous cyclophosphamide (ivCYC) and 24 rituximab (RTX) as induction therapy. Patients with ivCYC induction failure more frequently had PR3-ANCA (93% vs 70%, P = 0.02), relapsing disease (41% vs 7%, P < 0.001) and orbital mass (15% vs 0%, P < 0.01) compared with controls. Patients with disease progression despite RTX induction therapy more frequently had renal involvement (67% vs 25%, P = 0.02) with renal failure (serum creatinine >100 µmol/l in 42% vs 8%, P = 0.02) compared with controls. After salvage therapy, remission was achieved at 6 months in 35 (69%) patients. The most frequent salvage therapy was switching from ivCYC to RTX (or vice versa), showing an efficacy in 21/29 (72%). Remission was achieved in nine (50%) patients with inappropriate response to ivCYC, while in patients with progression after RTX induction, remission was achieved in four (100%) who received ivCYC (with or without immunomodulatory therapy), but only in three (50%) after adding immunomodulatory therapy alone. Conclusion: In patients with induction failure, characteristics of GPA, salvage therapies and their efficacy vary according to induction therapy and failure modality.Keywords
This publication has 25 references indexed in Scilit:
- Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated VasculitisArthritis & Rheumatism, 2013
- Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysisAnnals of the Rheumatic Diseases, 2013
- Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestationsAnnals of the Rheumatic Diseases, 2012
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisNew England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- B‐cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort studyClinical Otolaryngology, 2009
- A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2009
- Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosisArthritis & Rheumatism, 2009
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals of the Rheumatic Diseases, 2007
- Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestationsAnnals of the Rheumatic Diseases, 2006